Download | < Back |
14 Oct 2021 | |
Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company has received approval of Korean Ministry of Food and Drug Safety (Korean FDA) for Company's Pharmaceuticals API products 'IBUPROFEN and 'FENOFIBRATE'. The approval of Korean FDA re-establishes the Company's efforts to keep the highest quality standards and to increase presence in the regulated markets. This will strengthen Company's presence in South Korean market.<BR> <BR> | |
View all announcements for IOL CHEMICALS & PHARMACEUTICALS LTD. | Source: BSE India |